Compared side by side
Tirzepatide vs liraglutide: how they differ
The short answer
Liraglutide is a GLP-1 receptor agonist given as a daily shot, with a half-life of about 13 hours; tirzepatide activates the GLP-1 and GIP receptors and, with a half-life of about 5 days, is taken weekly. Both are FDA-approved, liraglutide as Victoza and Saxenda, tirzepatide as Mounjaro and Zepbound. Commonly reported: appetite drops and meals end sooner on liraglutide, less dramatically than on tirzepatide, whose appetite suppression users describe as very strong.
Side by side
| Compared | Tirzepatide | Liraglutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Mounjaro, Zepbound, LY3298176 | Victoza, Saxenda, Liraglutide injection |
| What it is | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). | The predecessor to semaglutide: a GLP-1 receptor agonist that reduces appetite and improves blood sugar control, given as a daily injection rather than weekly. |
| How it works | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. | GLP-1 receptor agonist and predecessor to semaglutide. Stimulates insulin secretion, reduces glucagon, slows gastric emptying, and reduces appetite. Shorter half-life than semaglutide requiring daily dosing. FDA approved for type 2 diabetes (Victoza) and obesity (Saxenda). The labels step the dose up from 0.6 mg to minimize GI side effects. |
| Commonly reported | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). | Appetite drops and meals end sooner, though less dramatically than on semaglutide or tirzepatide, with nausea during the climb to 3 mg. FDA-approved for diabetes (Victoza) and obesity (Saxenda), with one of the longest track records of any GLP-1 drug. |
| Studied range | FDA label: 2.5–15 mg, starting dose 2.5 mg. | FDA label: 0.6–3 mg, starting dose 0.6 mg. |
| How often | Weekly | Daily SubQ |
| Half-life | ~5 days (FDA label) | ~13 hours |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. | FDA-approved for daily use. Community uses continuously or until goal reached. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue | Nausea, vomiting, diarrhea, constipation, pancreatitis risk, thyroid C-cell tumor risk (animal data) |
- Category
- TirzepatideMetabolic & GLP-1
- LiraglutideMetabolic & GLP-1
- Also known as
- TirzepatideMounjaro, Zepbound, LY3298176
- LiraglutideVictoza, Saxenda, Liraglutide injection
- What it is
- TirzepatideThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
- LiraglutideThe predecessor to semaglutide: a GLP-1 receptor agonist that reduces appetite and improves blood sugar control, given as a daily injection rather than weekly.
- How it works
- TirzepatideDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
- LiraglutideGLP-1 receptor agonist and predecessor to semaglutide. Stimulates insulin secretion, reduces glucagon, slows gastric emptying, and reduces appetite. Shorter half-life than semaglutide requiring daily dosing. FDA approved for type 2 diabetes (Victoza) and obesity (Saxenda). The labels step the dose up from 0.6 mg to minimize GI side effects.
- Commonly reported
- TirzepatideVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
- LiraglutideAppetite drops and meals end sooner, though less dramatically than on semaglutide or tirzepatide, with nausea during the climb to 3 mg. FDA-approved for diabetes (Victoza) and obesity (Saxenda), with one of the longest track records of any GLP-1 drug.
- Studied range
- TirzepatideFDA label: 2.5–15 mg, starting dose 2.5 mg.
- LiraglutideFDA label: 0.6–3 mg, starting dose 0.6 mg.
- How often
- TirzepatideWeekly
- LiraglutideDaily SubQ
- Half-life
- Tirzepatide~5 days (FDA label)
- Liraglutide~13 hours
- Route
- TirzepatideSubQ injection
- LiraglutideSubQ injection
- Typical run
- TirzepatideFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
- LiraglutideFDA-approved for daily use. Community uses continuously or until goal reached.
- Evidence
- TirzepatideEstablished: clinical trials or FDA-approved use exists
- LiraglutideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- TirzepatideNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue
- LiraglutideNausea, vomiting, diarrhea, constipation, pancreatitis risk, thyroid C-cell tumor risk (animal data)
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Tirzepatide
- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course
Liraglutide
- Day 1–14 · 0.6 mg Starting dose — GI is the main thing
- Day 14–42 Titrating up — appetite really drops
- Day 42–168 Steady loss at target dose
- Day 168–365 Maintenance and long game
Questions people ask
How long do tirzepatide and liraglutide last?
The half-life of tirzepatide is ~5 days (FDA label). The half-life of liraglutide is ~13 hours.
How often are tirzepatide and liraglutide taken?
Tirzepatide: weekly. Route: SubQ injection. Liraglutide: daily SubQ. Route: SubQ injection.
How are tirzepatide and liraglutide dosed in research?
The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The FDA label range for liraglutide is 0.6–3 mg, with a 0.6 mg starting dose.
What are the common side effects of tirzepatide and liraglutide?
For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For liraglutide: nausea, vomiting, diarrhea, constipation, pancreatitis risk, thyroid C-cell tumor risk (animal data).